Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsInfectious Disease

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1400726

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1400726

Rapid Influenza Diagnostic Tests Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

PUBLISHED:
PAGES: 242 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The global Rapid Influenza Diagnostic Tests Market is experiencing robust growth, with total revenues reaching approximately US$ 1.1 billion in 2024. The market to an estimated valuation of US$ 2.1 billion by the end of 2031.

Global Influenza Prevalence Drives Demand

The rising global prevalence of influenza has led to an increased demand for efficient diagnostic methods. Influenza primarily affects vulnerable populations, including the elderly and children, and can lead to severe comorbidities in elderly individuals (aged 65 and older) with weakened immune systems.

Government Initiatives Support Market Growth

Governmental bodies worldwide are investing in the development of novel rapid influenza diagnostic tests, driven by the increase in epidemics and pandemics in recent years. These initiatives are expected to foster market expansion on a global scale.

Advantages of Rapid Influenza Diagnostic Tests

The adoption of quick influenza diagnostic tests offers numerous advantages, including early detection and prevention of influenza. Early detection plays a crucial role in preventing the spread of the virus and initiating timely treatment.

Key Market Growth Drivers

  • 1. Early Detection and Prevention of Influenza: Rapid diagnostic tests aid in the early detection of influenza, a highly transmissible infection. Early detection is essential in preventing severe health complications and death.
  • 2. Technological Advancements in Diagnostic Equipment: The emergence of rapid molecular assays and nucleic acid tests (NATs) has improved the sensitivity and specificity of influenza diagnosis, enabling quicker and more accurate results.
  • 3. Growing Awareness of Benefits of Early Diagnosis: Organizations and healthcare providers are promoting early viral disease identification to minimize disease-related mortality and make informed medical decisions.

Market Challenges

  • 1. False Negative Results: Sensitivity and specificity are crucial factors affecting the accuracy of rapid influenza diagnostic kits. The antigenic diversity of influenza viruses contributes to the complexity of these tests.
  • 2. Stringent Guidelines: Strict regulatory guidelines for new diagnostic test approvals can restrict market growth, impacting accessibility and pricing.

Booming U.S. Market

The United States leads the North American market for rapid influenza diagnostic tests due to a high occurrence of infectious diseases, rising hospitalizations, and influenza prevalence.

Lucrative German Market

Germany holds the majority of the European market share for rapid influenza diagnostic tests, driven by increased influenza prevalence, supportive government initiatives, and the presence of key players.

Prominent Market in Japan

Japan's growing market for quick influenza diagnostic tests is attributed to its well-developed healthcare system, favorable laws and insurance, extensive research into diagnostic technologies for influenza, and the presence of foreign companies.

Competitive Landscape

The market for rapid influenza diagnostic tests is consolidated, with companies focusing on launching new products, diversifying their customer bases, and obtaining regulatory permissions to expand globally.

Key Companies Profile

  • Thermo Fisher Scientific Inc.
  • Hologic
  • Quidel Corporation
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Becton Dickinson and Company
  • Danaher Corporation
  • Meridian Bioscience
  • bioMerieux SA
  • Luminex Corporation
  • Siemens Healthineers AG
  • GenMark Diagnostics
  • Sekisui Diagnostics
  • LLC altona Diagnostics GmbH
  • SA Scientific
  • ELITech Group

Market Segmentation

Principle:

  • Immunochromatographic Assays
  • Immunofluorescence Assays
  • Nucleic Acid Amplification Test (NAAT)

Test Type:

  • Influenza A Test
  • Influenza B Test
  • Influenza A+B Test

Sample Type:

  • Throat Swab
  • Nasal Swab
  • Nasal Aspirate
  • Nasal Wash
  • Nasopharyngeal Swab
  • Nasopharyngeal Aspirate
  • Nasopharyngeal Wash
  • Others

End User:

  • Hospitals
  • Diagnostic Centers
  • Nursing Homes
  • Office-based Settings
  • Urgent Care Centers
  • Retail Pharmacy Clinics
  • Schools & Universities
  • Public Health Camps
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Rapid Influenza Diagnostic Tests Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Rapid Influenza Diagnostic Tests Market Outlook, 2018 - 2031

  • 3.1. Global Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Immunochromatographic Assays
      • 3.1.1.2. Immunofluorescence Assays
      • 3.1.1.3. Nucleic Acid Amplification Test (NAAT)
  • 3.2. Global Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Influenzas A Test
      • 3.2.1.2. Influenza B Test
      • 3.2.1.3. Influenza A+B Test
  • 3.3. Global Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Throat Swab
      • 3.3.1.2. Nasal Swab
      • 3.3.1.3. Nasal Aspirate
      • 3.3.1.4. Nasal Wash
      • 3.3.1.5. Nasopharyngeal Swab
      • 3.3.1.6. Nasopharyngeal Aspirate
      • 3.3.1.7. Nasopharyngeal Wash
      • 3.3.1.8. Others
  • 3.4. Global Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospitals
      • 3.4.1.2. Diagnostic Centers
      • 3.4.1.3. Nursing Homes
      • 3.4.1.4. Office-based Settings
      • 3.4.1.5. Urgent Care Centers
      • 3.4.1.6. Retail Pharmacy Clinics
      • 3.4.1.7. Schools & Universities
      • 3.4.1.8. Public Health Camps
      • 3.4.1.9. Others
  • 3.5. Global Rapid Influenza Diagnostic Tests Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Rapid Influenza Diagnostic Tests Market Outlook, 2018 - 2031

  • 4.1. North America Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Immunochromatographic Assays
      • 4.1.1.2. Immunofluorescence Assays
      • 4.1.1.3. Nucleic Acid Amplification Test (NAAT)
  • 4.2. North America Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Influenzas A Test
      • 4.2.1.2. Influenza B Test
      • 4.2.1.3. Influenza A+B Test
  • 4.3. North America Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Throat Swab
      • 4.3.1.2. Nasal Swab
      • 4.3.1.3. Nasal Aspirate
      • 4.3.1.4. Nasal Wash
      • 4.3.1.5. Nasopharyngeal Swab
      • 4.3.1.6. Nasopharyngeal Aspirate
      • 4.3.1.7. Nasopharyngeal Wash
      • 4.3.1.8. Others
  • 4.4. North America Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospitals
      • 4.4.1.2. Diagnostic Centers
      • 4.4.1.3. Nursing Homes
      • 4.4.1.4. Office-based Settings
      • 4.4.1.5. Urgent Care Centers
      • 4.4.1.6. Retail Pharmacy Clinics
      • 4.4.1.7. Schools & Universities
      • 4.4.1.8. Public Health Camps
      • 4.4.1.9. Others
  • 4.5. North America Rapid Influenza Diagnostic Tests Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 4.5.1.2. U.S. Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.3. U.S. Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.4. U.S. Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 4.5.1.5. Canada Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 4.5.1.6. Canada Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.7. Canada Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.8. Canada Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Rapid Influenza Diagnostic Tests Market Outlook, 2018 - 2031

  • 5.1. Europe Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Immunochromatographic Assays
      • 5.1.1.2. Immunofluorescence Assays
      • 5.1.1.3. Nucleic Acid Amplification Test (NAAT)
  • 5.2. Europe Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Influenzas A Test
      • 5.2.1.2. Influenza B Test
      • 5.2.1.3. Influenza A+B Test
  • 5.3. Europe Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Throat Swab
      • 5.3.1.2. Nasal Swab
      • 5.3.1.3. Nasal Aspirate
      • 5.3.1.4. Nasal Wash
      • 5.3.1.5. Nasopharyngeal Swab
      • 5.3.1.6. Nasopharyngeal Aspirate
      • 5.3.1.7. Nasopharyngeal Wash
      • 5.3.1.8. Others
  • 5.4. Europe Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospitals
      • 5.4.1.2. Diagnostic Centers
      • 5.4.1.3. Nursing Homes
      • 5.4.1.4. Office-based Settings
      • 5.4.1.5. Urgent Care Centers
      • 5.4.1.6. Retail Pharmacy Clinics
      • 5.4.1.7. Schools & Universities
      • 5.4.1.8. Public Health Camps
      • 5.4.1.9. Others
  • 5.5. Europe Rapid Influenza Diagnostic Tests Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 5.5.1.2. Germany Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.3. Germany Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.4. Germany Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.5. U.K. Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 5.5.1.6. U.K. Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.7. U.K. Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.8. U.K. Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.9. France Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 5.5.1.10. France Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.11. France Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.12. France Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.13. Italy Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 5.5.1.14. Italy Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.15. Italy Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.16. Italy Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.17. Turkey Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 5.5.1.18. Turkey Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.19. Turkey Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.20. Turkey Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.21. Russia Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 5.5.1.22. Russia Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.23. Russia Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.24. Russia Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Immunochromatographic Assays
      • 6.1.1.2. Immunofluorescence Assays
      • 6.1.1.3. Nucleic Acid Amplification Test (NAAT)
  • 6.2. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Influenzas A Test
      • 6.2.1.2. Influenza B Test
      • 6.2.1.3. Influenza A+B Test
  • 6.3. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Throat Swab
      • 6.3.1.2. Nasal Swab
      • 6.3.1.3. Nasal Aspirate
      • 6.3.1.4. Nasal Wash
      • 6.3.1.5. Nasopharyngeal Swab
      • 6.3.1.6. Nasopharyngeal Aspirate
      • 6.3.1.7. Nasopharyngeal Wash
      • 6.3.1.8. Others
  • 6.4. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospitals
      • 6.4.1.2. Diagnostic Centers
      • 6.4.1.3. Nursing Homes
      • 6.4.1.4. Office-based Settings
      • 6.4.1.5. Urgent Care Centers
      • 6.4.1.6. Retail Pharmacy Clinics
      • 6.4.1.7. Schools & Universities
      • 6.4.1.8. Public Health Camps
      • 6.4.1.9. Others
  • 6.5. Asia Pacific Rapid Influenza Diagnostic Tests Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 6.5.1.2. China Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.3. China Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.4. China Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.5. Japan Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 6.5.1.6. Japan Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.7. Japan Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.8. Japan Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.9. South Korea Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 6.5.1.10. South Korea Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.11. South Korea Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.12. South Korea Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.13. India Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 6.5.1.14. India Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.15. India Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.16. India Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Rapid Influenza Diagnostic Tests Market Outlook, 2018 - 2031

  • 7.1. Global Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Immunochromatographic Assays
      • 7.1.1.2. Immunofluorescence Assays
      • 7.1.1.3. Nucleic Acid Amplification Test (NAAT)
  • 7.2. Latin America Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Influenzas A Test
      • 7.2.1.2. Influenza B Test
      • 7.2.1.3. Influenza A+B Test
  • 7.3. Latin America Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Throat Swab
      • 7.3.1.2. Nasal Swab
      • 7.3.1.3. Nasal Aspirate
      • 7.3.1.4. Nasal Wash
      • 7.3.1.5. Nasopharyngeal Swab
      • 7.3.1.6. Nasopharyngeal Aspirate
      • 7.3.1.7. Nasopharyngeal Wash
      • 7.3.1.8. Others
  • 7.4. Latin America Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospitals
      • 7.4.1.2. Diagnostic Centers
      • 7.4.1.3. Nursing Homes
      • 7.4.1.4. Office-based Settings
      • 7.4.1.5. Urgent Care Centers
      • 7.4.1.6. Retail Pharmacy Clinics
      • 7.4.1.7. Schools & Universities
      • 7.4.1.8. Public Health Camps
      • 7.4.1.9. Others
  • 7.5. Latin America Rapid Influenza Diagnostic Tests Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 7.5.1.2. Brazil Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.3. Brazil Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.4. Brazil Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.5.1.5. Mexico Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 7.5.1.6. Mexico Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.7. Mexico Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.8. Mexico Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.5.1.9. Argentina Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 7.5.1.10. Argentina Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.11. Argentina Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.12. Argentina Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, by Principle, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Immunochromatographic Assays
      • 8.1.1.2. Immunofluorescence Assays
      • 8.1.1.3. Nucleic Acid Amplification Test (NAAT)
  • 8.2. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Influenzas A Test
      • 8.2.1.2. Influenza B Test
      • 8.2.1.3. Influenza A+B Test
  • 8.3. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, by Sample Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Throat Swab
      • 8.3.1.2. Nasal Swab
      • 8.3.1.3. Nasal Aspirate
      • 8.3.1.4. Nasal Wash
      • 8.3.1.5. Nasopharyngeal Swab
      • 8.3.1.6. Nasopharyngeal Aspirate
      • 8.3.1.7. Nasopharyngeal Wash
      • 8.3.1.8. Others
  • 8.4. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospitals
      • 8.4.1.2. Diagnostic Centers
      • 8.4.1.3. Nursing Homes
      • 8.4.1.4. Office-based Settings
      • 8.4.1.5. Urgent Care Centers
      • 8.4.1.6. Retail Pharmacy Clinics
      • 8.4.1.7. Schools & Universities
      • 8.4.1.8. Public Health Camps
      • 8.4.1.9. Others
  • 8.5. Middle East & Africa Rapid Influenza Diagnostic Tests Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 8.5.1.2. GCC Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.3. GCC Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.4. GCC Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.5. South Africa Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 8.5.1.6. South Africa Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.7. South Africa Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.8. South Africa Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.9. Egypt Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 8.5.1.10. Egypt Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.11. Egypt Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.12. Egypt Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.13. Nigeria Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 8.5.1.14. Nigeria Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.15. Nigeria Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.16. Nigeria Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Rapid Influenza Diagnostic Tests Market by Principle, Value (US$ Bn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Rapid Influenza Diagnostic Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Rapid Influenza Diagnostic Tests Market by Sample Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Rapid Influenza Diagnostic Tests Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. by Sample Type vs by Test Type Heatmap
  • 9.2. Manufacturer vs by Test Type Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Thermo Fisher Scientific Inc
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Hologic
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Quidel Corporation
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. F. Hoffmann-La Roche AG
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Abbott Laboratories
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Becton Dickinson and Company
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Danaher Corporation
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Meridian Bioscience
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. bioMerieux SA
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Luminex Corporation
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Siemens Healthineers AG
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. GenMark Diagnostics
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Sekisui Diagnostics
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. LLC altona Diagnostics GmbH
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. SA Scientific
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development
    • 9.5.16. ELITech Group
      • 9.5.16.1. Company Overview
      • 9.5.16.2. Product Portfolio
      • 9.5.16.3. Financial Overview
      • 9.5.16.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!